Guangshengtang announced that the Phase III clinical trial of Nericavir GST-HG141, an innovative drug for hepatitis B treatment under development by Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the holding subsidiary of the company, completed the first case of the test subjects successfully enrolled and administered at Shulan Hospital on July 25, 2025. GST-HG141 is a novel hepatitis B core protein/nucleocapsid modulator. It is a new class of anti-hepatitis B virus drugs under development with a new mechanism. The company has its own global intellectual property rights. The phase III clinical trial is a “randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of GST-HG141 for the combined treatment of patients with poor response to chronic hepatitis B antiviral drugs.”

Guangshengtang announced that the Phase III clinical trial of Nericavir GST-HG141, an innovative drug for hepatitis B treatment under development by Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the holding subsidiary of the company, completed the first case of the test subjects successfully enrolled and administered at Shulan Hospital on July 25, 2025. GST-HG141 is a novel hepatitis B core protein/nucleocapsid modulator. It is a new class of anti-hepatitis B virus drugs under development with a new mechanism. The company has its own global intellectual property rights. The phase III clinical trial is a “randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of GST-HG141 for the combined treatment of patients with poor response to chronic hepatitis B antiviral drugs.”